SciSparc Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.1
- Dividend yield
- –
About SciSparc
Pharmaceutical Preparations, SIC 2834
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on creating and developing technologies and therapeutic assets based on cannabinoid treatments. Through its majority-owned subsidiary, NeuroThera Labs Inc., the company advances clinical programs utilizing Δ9-tetrahydrocannabinol and non-psychoactive cannabidiol to address central nervous system conditions. Its development pipeline includes SCI-110 for Tourette syndrome, Alzheimer’s disease, and agitation, as well as SCI-210 for autism spectrum disorder and status epilepticus. In addition, the company oversees early commercial initiatives for CannAmide, an oral palmitoylethanolamide tablet formulation intended for Canadian retail pharmacies, alongside an eCommerce subsidiary marketing hemp seed oil products on Amazon Marketplace.
The company operates primarily out of Israel, where it conducts its core research and development activities and corporate functions. Additional development operations, public listings, and sales channels run through Canadian corporate entities and global third-party online retail platforms. SciSparc maintains its executive headquarters and primary corporate offices in Tel Aviv, Israel.
Summary of the business section of SciSparc's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SciSparc Ltd.
- Founded
- 2004
- Headquarters
- Tel Aviv, L3
- Address
- 20 Raul Wallenberg Street, Tower A 6971916
- Phone
- 972-3-6103100
- Website
- scisparc.com
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- SPRC
- Exchange
- Nasdaq
- IPO date
- Mar 22, 2017
- Shares outstanding
- 0M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-9 reverse, Mar 4, 2026; 1-for-21 reverse, Jul 22, 2025; 1-for-21 reverse, Jul 3, 2025; 1-for-26 reverse, Sep 28, 2023
- SEC CIK
- 1611746
- CUSIP
- M82618121
- ISIN
- USM826181218
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Oz Adler | CEO and CFO | 11,058 |
| Adi Zuloff-Shani | Chief Technology Officer | 5,528 |
| Lior Vider | Director | 3,649 |
| Liat Sidi | Director | 3,649 |
| Amnon Ben Shay | Director | 3,649 |
| Moshe Revach | Director | 3,649 |
| Itschak Shrem | Director | 11,058 |
| Alon Dayan | Director | 3,649 |
| Amitay Weiss | Director | 11,058 |
Employees
Headcount reported in annual reports
“On December 31, 2023, we had 3 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 26, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 28, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 20, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 28, 2021 | Name change | Name changed from Therapix Biosciences Ltd. to SciSparc Ltd./ADR |
| Sep 22, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| May 1, 2019 | Late filing | Notification of late filing |
| Mar 22, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 21, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |